|1.||Leamon, Christopher P: 9 articles (10/2014 - 05/2007)|
|2.||Reddy, Joseph A: 6 articles (10/2014 - 05/2007)|
|3.||Vetzel, Marilynn: 5 articles (04/2014 - 05/2007)|
|4.||Messmann, Richard A: 5 articles (12/2013 - 12/2009)|
|5.||Dorton, Ryan: 4 articles (04/2014 - 05/2007)|
|6.||Sausville, Edward A: 4 articles (12/2013 - 12/2009)|
|7.||Klein, Patrick J: 4 articles (11/2012 - 09/2009)|
|8.||Vlahov, Iontcho R: 4 articles (02/2011 - 05/2007)|
|9.||Westrick, Elaine: 4 articles (02/2011 - 05/2007)|
|10.||Edelman, Martin J: 3 articles (11/2012 - 05/2012)|
02/01/2011 - "Whereas both compounds could cure tumor-bearing mice reproducibly, EC0489 differed from EC145 with i) a shorter elimination half-life, ii) approximately 70% decrease in bile clearance, iii) a 4-fold increase in urinary excretion, and iv) improved tolerability in rodents. "
12/01/2009 - "In conclusion, EC145 is rapidly distributed and eliminated in cancer patients. "
10/01/2007 - "Additional preclinical studies are therefore warranted to better understand EC145's breadth of activity against FR-positive tumors."
11/10/2012 - "EC145 administered by bolus injection or as a 1-hour infusion at a dose of 2.5 mg on days 1, 3, and 5 and days 15, 17, and 19 of a 28-day cycle has an acceptable safety profile in patients with advanced cancer. "
10/01/2007 - "Furthermore, EC145 was not found to be active against a FR-negative tumor model. "
|2.||Ovarian Neoplasms (Ovarian Cancer)
07/01/2014 - "We review the development of vintafolide (EC145), a folic acid-desacetylvinblastine conjugate, the predictive utility of a FR-targeted imaging agent, technetium-(99)m-etarfolatide (EC20), the challenges in proving survival advantage, and other approaches to exploiting FR as a target in ovarian cancer."
03/01/2014 - "Vintafolide (EC145) is a novel folate-conjugated vinca alkaloid (desacetylvinblastine hydrazide; DAVBLH) that binds with high affinity to the folate receptor (FR), expressed in a majority of epithelial ovarian cancers. "
01/01/2014 - "Our aim was to review the profile of vintafolide (EC145) and its rationale for use in platinum-resistant ovarian cancer. "
01/01/2014 - "Profile of vintafolide (EC145) and its use in the treatment of platinum-resistant ovarian cancer."
12/10/2013 - "Vintafolide (EC145) is a folic acid-desacetylvinblastine conjugate that binds to the folate receptor (FR), which is expressed on the majority of epithelial ovarian cancers. "
12/01/2009 - "EC145-induced constipation occurs at a higher frequency in the patients with lower EC145 clearance, where the drug exposure tends to be higher."
02/01/2011 - "During a phase I trial of EC145 (a folate-targeted vinca alkaloid conjugate), constipation was identified as the dose-limiting toxicity, probably from a nonfolate receptor-related liver clearance process capable of releasing unconjugated vinca alkaloid from EC145 and shuttling it to the bile. "
|4.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
|1.||Folic Acid (Vitamin M)
|3.||Adenocarcinoma of lung
|4.||Ovarian epithelial cancer
|5.||pegylated liposomal doxorubicin
|2.||Drug Therapy (Chemotherapy)
|3.||Heterologous Transplantation (Xenotransplantation)